These products are intended for research purposes only and are not for human consumption. Not FDA approved. Not intended to diagnose, treat, cure, or prevent any disease.

Out of Stock

Peptide Reference Standard

LUV TRZ2

Name: LUV TRZ2
Brand: Luvaminos
SKU: luv-trz2
Availability: OutOfStock

Be the first to review

For Research Purposes OnlyNot for Human Consumption

Third-Party TestedPurity Standards

Almost sold outFinal units

Total

$39.99

Size

Quantity

1

Bundle & Save

View Studies

Restock alert

Notify me when it’s back

Quality & methods

Reviews

Research community reviews

Reviews reflect individual research observations only. All products are for research use only — not for human consumption.

No reviews yet. Be the first to share your research observations.

Purchased this? Leave a review from your account.

Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.

Molecular Profile

Mechanism & Target Class

Storage & Handling

References

Primary Database

View this compound in the Research Library →

Reviews

3
Sun B, Li Z, Xiao Y, et al. (2022). Nat Rev Drug Discov — Review of LUV TRZ2 receptor pharmacology and pharmacokinetic characterization
DOI: 10.1038/s41573-022-00177-5 PubMed 35818715
4
Min T, et al. (2021). Diabetes Ther — Narrative review of dual GIP/LUV TRZ2 receptor agonism and the SURPASS clinical trial program
DOI: 10.1007/s13300-020-00981-0 PubMed 33325008
5
Nowak M, et al. (2022). Endokrynol Pol — Narrative review of dual GIP/LUV TRZ2 receptor agonist pharmacology and metabolic activity
DOI: 10.5603/EP.a2022.0029 PubMed 35593668
6
Forzano I, et al. (2022). Int J Mol Sci — Systematic review of clinical trial data for LUV TRZ2 dual incretin receptor agonist
DOI: 10.3390/ijms232314631 PubMed 36498958
7
Tang Y, et al. (2022). Front Pharmacol — Systematic review and meta-analysis of LUV TRZ2 dual incretin receptor agonist clinical study data
DOI: 10.3389/fphar.2022.1016639 PubMed 36569320
8
Bhagavathula AS, et al. (2021). Pharmaceuticals (Basel) — Systematic review and meta-analysis of randomized phase II/III clinical studies of LUV TRZ2
DOI: 10.3390/ph14100991 PubMed 34681215
9
Campbell JE, et al. (2023). Cell Metab — Review of GIPR/GLP-1R dual agonist pharmacology, chemistry, physiology, and clinical applications
DOI: 10.1016/j.cmet.2023.07.010 PubMed 37591245

Clinical

10
Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). N Engl J Med — Phase 3 randomized clinical study (SURMOUNT-1); cited for study-design context
DOI: 10.1056/NEJMoa2206038 PubMed 35658024
11
Frias JP, Davies MJ, Rosenstock J, et al. (2021). N Engl J Med — Phase 3 randomized clinical study (SURPASS-2); cited for study-design context
DOI: 10.1056/NEJMoa2107519 PubMed 34170647
12
Frias JP, et al. (2018). Lancet — Phase 2 randomized clinical study of dual GIP/LUV TRZ2 peptide; cited for study-design context
DOI: 10.1016/S0140-6736(18)32260-8 PubMed 30293770

Primary research

17
Sun B, Willard FS, Feng D, et al. (2022). Proc Natl Acad Sci U S A — Cryo-EM structural study of GLP-1R and GIPR complexes with LUV TRZ2
DOI: 10.1073/pnas.2116506119 PubMed 35333651
18
Willard FS, Douros JD, Gabe MBN, et al. (2020). JCI Insight — In vitro receptor pharmacology of LUV TRZ2 at GIPR and GLP-1R — biased signaling characterization
DOI: 10.1172/jci.insight.140532 PubMed 32974048
19
Coskun T, et al. (2018). Mol Metab — Preclinical pharmacological characterization of LUV TRZ2 as a dual incretin receptor agonist
DOI: 10.1016/j.molmet.2018.09.009
20

13

Ludvik B, et al. (2021). Lancet — Randomized clinical study (SURPASS-3); cited for study-design context

DOI: 10.1016/S0140-6736(21)01443-4 PubMed 34370970

14

Del Prato S, et al. (2021). Lancet — Phase 3 randomized clinical study (SURPASS-4); cited for study-design context

DOI: 10.1016/S0140-6736(21)02188-7 PubMed 34672967

15

Dahl D, et al. (2022). JAMA — Phase 3 randomized clinical study (SURPASS-5); cited for study-design context

DOI: 10.1001/jama.2022.0078 PubMed 35133415

16

Garvey WT, et al. (2023). Lancet — Phase 3 randomized clinical study (SURMOUNT-2); cited for study-design context

DOI: 10.1016/S0140-6736(23)01200-X PubMed 37385275

Samms RJ, et al. (2021). J Clin Invest — Preclinical study: GIPR agonism and insulin sensitization in a rodent metabolic model

DOI: 10.1172/JCI146353 PubMed 34003802

21

El K, et al. (2023). Nat Metab — In vitro study: GIPR required for LUV TRZ2 incretin co-agonist hormone secretion from human islets

DOI: 10.1038/s42255-023-00811-0 PubMed 37277609

22

Regmi A, et al. (2024). Cell Metab — In vitro/preclinical study: LUV TRZ2 modulates adipocyte nutrient metabolism via long-acting GIPR activation

DOI: 10.1016/j.cmet.2024.05.010 PubMed 38878772